NRx Pharmaceuticals, Inc. (NRXP): Price and Financial Metrics


NRx Pharmaceuticals, Inc. (NRXP): $1.23

-0.02 (-1.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NRXP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NRXP Stock Price Chart Interactive Chart >

Price chart for NRXP

NRXP Price/Volume Stats

Current price $1.23 52-week high $3.54
Prev. close $1.25 52-week low $0.49
Day low $1.18 Volume 246,865
Day high $1.26 Avg. volume 338,706
50-day MA $1.22 Dividend yield N/A
200-day MA $0.97 Market Cap 83.26M

NRx Pharmaceuticals, Inc. (NRXP) Company Bio


NRX Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company specializes in researching investigational medicines and is engaged in the development of medicines and vaccines for Covid-19, other respiratory conditions, suicidal depression, and PTSD.


NRXP Latest News Stream


Event/Time News Detail
Loading, please wait...

NRXP Latest Social Stream


Loading social stream, please wait...

View Full NRXP Social Stream

Latest NRXP News From Around the Web

Below are the latest news stories about NRX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NRXP as an investment opportunity.

NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101.

Yahoo | January 19, 2023

NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates ("6th Annual NIF"). The forum takes place Sunday, January 8, 2023, as part of the activities surrounding the annual J.P. Morgan

Yahoo | January 5, 2023

NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that its first clinical trial site has been contracted (with others expected in near future) and that first dosing of patients is expected in early 2023. This Phase 3 clinical trial of NRX-101 is for the treatment of Severe Bipolar Depression with Acute Suicidal Ideation and Behavior ("SBD-ASIB"), a lethal condition that currently takes the lives of thousan

Yahoo | January 3, 2023

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

Relief Therapeutics Holding SA / Key word(s): Legal Matter Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements 20-Dec-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.

Wallstreet:Online | December 20, 2022

Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

Relief Therapeutics Holding SA / Key word(s): Legal Matter Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements 20-Dec-2022 / 07:00 CET/C…

Finanz Nachrichten | December 20, 2022

Read More 'NRXP' Stories Here

NRXP Price Returns

1-mo 11.82%
3-mo 51.85%
6-mo 55.11%
1-year -56.99%
3-year N/A
5-year -87.32%
YTD 10.81%
2022 -76.78%
2021 -80.41%
2020 130.19%
2019 3.92%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5974 seconds.